Drugs / XALNESIRAN
XALNESIRAN
also known as
Dcr-a1at free acid · DCR-HBVS · Dcr-hbvs free acid · DCR-S219 · DCR-S219 FREE ACID · Rg-6346 free acid · RG6346 · Ro-7445482 free acid · +1 more
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03772249 | Dec 2018 → Jul 2022 | chronic hepatitis B virus infection | Dicerna Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04225715 | Jul 2020 → Jul 2024 | chronic hepatitis B virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XALNESIRAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095159 ↗ |
| Known as | Dcr-a1at free acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095159 ↗ |
| Known as | DCR-HBVS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03772249 ↗ |
| Known as | Dcr-hbvs free acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095159 ↗ |
| Known as | DCR-S219 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095159 ↗ |
| Known as | DCR-S219 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095159 ↗ |
| Known as | Rg-6346 free acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095159 ↗ |
| Known as | RG6346 | “RG6346 is an N-acetyl-D-galactosamine (GalNAc)-conjugated, double-stranded RNA interference agent targeting the HBV genome S-region.” PMID 37524230 ↗ Jul 2023 |
| Known as | Ro-7445482 free acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095159 ↗ |
| Known as | RO7445482 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04225715 ↗ |
| Modality | Small interfering RNA (siRNA) | “double-stranded RNA interference agent” PMID 37524230 ↗ Jul 2023 |
| Route | Subcutaneous | “Subcutaneous injection of 0.1mg/kg of DCR-HBVS” NCT03772249 ↗ |